Sugi Predict

Sugi Predict / Compounds / SCHEMBL2011443

SCHEMBL2011443

SCHEMBL2011443

NS(=O)(=O)c1ccc2c(c1)CCC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 9/20 1.00
▸ CA2 P00918 9/20 1.00
▸ CA12 O43570 5/20 1.00
▸ CA7 P43166 3/20 1.00
▸ CA14 Q9ULX7 2/20 1.00
▸ ADRA2A P08913 1/20 0.61
▸ PNMT P11086 1/20 0.61
▸ ADRA2B P18089 1/20 0.61
▸ ADRA2C P18825 1/20 0.61
▸ CA9 Q16790 4/20 0.59
▸ PTPN7 P35236 1/20 0.58
▸ PTGES2 Q9H7Z7 2/20 0.56
▸ MEN1 O00255 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ RXFP1 Q9HBX9 1/20 0.53
▸ STS P08842 1/20 0.52
▸ PTGS1 P23219 1/20 0.47
▸ PTGS2 P35354 1/20 0.47
▸ DPP4 P27487 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29519756 1.00 CA1 (1.00) CA1CA2CA12CA7CA14
SCHEMBL8879406 0.96 CA1 (0.92) CA1CA2CA12CA7CA14
SCHEMBL6955385 0.82 PNMT (0.81) CA1CA2CA12CA7CA14
Trifluoroacetamide SCHEMBL14335598 0.82 CA1 (0.68) CA1CA2CA12CA7CA14
Hydrochloric Acid SCHEMBL11765973 0.81 PNMT (0.78) CA1CA2CA12CA7CA14
SCHEMBL6761562 0.81 CA1 (0.67) CA1CA2CA12CA7CA14
SCHEMBL29649377 0.80 CA1 (0.66) CA1CA2CA12CA7CA14
SCHEMBL20638456 0.80 CA1 (0.66) CA1CA2CA12CA7CA14
SCHEMBL29649370 0.80 CA1 (0.66) CA1CA2CA12CA7CA14
SCHEMBL7135031 0.80 CA1 (0.66) CA1CA2CA12CA7CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107405320-B Pharmaceutical composition comprising metal lactate for the treatment of cancer 麦提麦迪制药有限公司 2023-06-20 — — CN claimed
US-20250326764-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS LLC (US) 2025-10-23 — — US disclosed
US-12312359-B2 Inhibitors of the menin-MLL interaction VITAE PHARMACEUTICALS, LLC (US) 2025-05-27 — — US disclosed
US-20240400502-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME UNIV QUEENSLAND (AU) 2024-12-05 — — US disclosed
US-20240228463-A1 SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME GENENTECH, INC. (US) 2024-07-11 — — US disclosed
US-11845715-B2 — — 2023-12-19 — — US disclosed
CN-107405320-B Pharmaceutical composition comprising metal lactate for the treatment of cancer 麦提麦迪制药有限公司 2023-06-20 — — CN disclosed
US-20230174541-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS, LLC 2023-06-08 — — US disclosed
US-20230104936-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-04-06 — — US disclosed
WO-2023028077-A1 SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME GENENTECH, INC. (US) 2023-03-02 — — WO disclosed
WO-2001030749-A1 NOVEL COMPOUNDS NEW PHARMA RESEARCH SWEDEN AB (SE) 2001-05-03 — — WO disclosed
WO-1998044799-A1 DIARYLSULFONYLUREAS FOR USE IN TREATING SECRETORY DIARRHEA ELI LILLY AND COMPANY (US) 1998-10-15 — — WO disclosed
US-5594028-A SULFONYLUREAS ELI LILLY AND COMPANY (US) 1997-01-14 — — US disclosed
EP-0606723-A1 Imidazolidin-2-one derivatives and their use as antitumor agents ELI LILLY AND COMPANY (US) 1994-07-20 — — EP disclosed
US-5270329-A 1-arylsulfonyl-imidazolidin-2-one derivatives ELI LILLY AND COMPANY (US) 1993-12-14 — — US disclosed
US-5116874-A Aminocarbonyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 1992-05-26 — — US disclosed
EP-0222475-B1 SULFONYL UREAS WITH ANTI-TUMOUR ACTIVITY ELI LILLY AND COMPANY (US) 1989-11-29 — — EP disclosed
EP-0222475-A1 Sulfonyl ureas with anti-tumour activity ELI LILLY AND COMPANY (US) 1987-05-20 — — EP disclosed
EP-0222475-A1 Sulfonyl ureas with anti-tumour activity ELI LILLY AND COMPANY (US) 1987-05-20 — — EP disclosed
US-3711564-A NOVEL SULFONYLAMINOPYRIMIDINES AND COMPOSITIONS CONTAINING THEM BOEHRINGER MANNHEIM GMBH 1973-01-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174541-A1 INHIBITORS OF THE MENIN-MLL INTERACTION MLLT1, MEN1, MLLT3 CA1 3906/4885CA2 4247/4885CA12 4400/4885
US-11845715-B2 — NLRP3, PYCARD, NOD1 CA1 4541/4885CA2 3818/4885CA12 4772/4885
US-20240400502-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME NLRP3, PYCARD, IAPP CA1 4141/4885CA2 2434/4885CA12 4653/4885
US-20240228463-A1 SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME CACNA1I, CACNA1B, CACNA1C CA1 442/4885CA2 95/4885CA12 1502/4885
US-12312359-B2 Inhibitors of the menin-MLL interaction MLLT1, MEN1, MLLT3 CA1 3906/4885CA2 4247/4885CA12 4400/4885
US-20230104936-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 CA1 1974/4885CA2 294/4885CA12 3100/4885
US-20250326764-A1 INHIBITORS OF THE MENIN-MLL INTERACTION MLLT1, MEN1, MLLT3 CA1 3906/4885CA2 4247/4885CA12 4400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.